Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage assets. RXRX's AI-driven drug discovery model is ambitious, but pipeline value ...
Management expressed confidence in achieving further milestones in 2025, supported by partnerships with Roche and Sanofi. CEO Gibson noted that the partnership milestones generated $45 million in cash ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results